Review
doi: 10.1097/00002826-199308000-00001.
Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation
Affiliations
- PMID: 8374912
- DOI: 10.1097/00002826-199308000-00001
Item in Clipboard
Review
Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation
Clin Neuropharmacol.
1993 Aug.
Abstract
This review assesses the efficacy and specificity of psychotropic medications used to control aberrant behavior in persons with mental retardation. It is concluded that neuroleptics, the most widely used psychotropic agents in this population, suppress aberrant behavior, but do so by suppressing behavior generally. An exception to this conclusion is that it may be possible to selectively suppress stereotyped behavior with neuroleptics. In addition, the empirical evidence indicates that, in some persons with mental retardation, opioid antagonists and methylphenidate are useful therapies for self-injurious behavior and hyperactivity, respectively. Lithium and beta-blockers are potentially useful for treating aggression.
Similar articles
-
Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation.J Autism Dev Disord. 1997 Feb;27(1):89-102. doi: 10.1023/a:1025825322955. J Autism Dev Disord. 1997. PMID: 9018584 No abstract available.
-
Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior.J Clin Psychiatry. 2003 Sep;64(9):1081-90. doi: 10.4088/jcp.v64n0914. J Clin Psychiatry. 2003. PMID: 14628984 Clinical Trial.
-
A review of pharmacological agents for self-injurious behavior.Prog Neuropsychopharmacol Biol Psychiatry. 1990;14 Suppl:S169-79. doi: 10.1016/0278-5846(90)90093-v. Prog Neuropsychopharmacol Biol Psychiatry. 1990. PMID: 2097670 Review.
-
Psychopharmacology and mental retardation: a 10 year review (1990-1999).Res Dev Disabil. 2000 Jul-Aug;21(4):263-96. doi: 10.1016/s0891-4222(00)00042-1. Res Dev Disabil. 2000. PMID: 10983783 Review.
-
Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions.Res Dev Disabil. 2003 May-Jun;24(3):149-57. doi: 10.1016/s0891-4222(03)00030-1. Res Dev Disabil. 2003. PMID: 12742384
Cited by
-
Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation.J Autism Dev Disord. 1997 Feb;27(1):89-102. doi: 10.1023/a:1025825322955. J Autism Dev Disord. 1997. PMID: 9018584 No abstract available.
-
Polypharmacy in the treatment of subjects with intellectual disability.J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S93-100. doi: 10.1007/s00702-014-1219-x. Epub 2014 May 25. J Neural Transm (Vienna). 2015. PMID: 24858727 Review.
-
Separate and combined effects of methylphenidate and a behavioral intervention on disruptive behavior in children with mental retardation.J Appl Behav Anal. 1996 Fall;29(3):305-19. doi: 10.1901/jaba.1996.29-305. J Appl Behav Anal. 1996. PMID: 8926223 Free PMC article. Clinical Trial.
-
Endogenous opiates: 1993.Peptides. 1994;15(8):1513-56. doi: 10.1016/0196-9781(94)90131-7. Peptides. 1994. PMID: 7700854 Free PMC article. Review.
-
Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities.Cochrane Database Syst Rev. 2009 Apr 15;2009(2):CD007011. doi: 10.1002/14651858.CD007011.pub2. Cochrane Database Syst Rev. 2009. PMID: 19370667 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources